Exploring optimal pharmacotherapy after bariatric surgery: where two worlds meet

Yska, J. P. 2017 [Groningen]: Rijksuniversiteit Groningen. 194 p.

Research output: ScientificDoctoral Thesis

Copy link to clipboard


  • Title and contents

    Final publisher's version, 165 KB, PDF-document

  • Chapter 1

    Final publisher's version, 526 KB, PDF-document

  • Chapter 2

    Final publisher's version, 237 KB, PDF-document

  • Chapter 3

    Final publisher's version, 477 KB, PDF-document

  • Chapter 4

    Final publisher's version, 746 KB, PDF-document

  • Chapter 5

    Final publisher's version, 511 KB, PDF-document

  • Chapter 6

    Final publisher's version, 530 KB, PDF-document

    Embargo ends: 02/06/2018

  • Chapter 7

    Final publisher's version, 776 KB, PDF-document

    Embargo ends: 02/06/2018

  • Chapter 8

    Final publisher's version, 1 MB, PDF-document

    Embargo ends: 02/06/2018

  • Chapter 9

    Final publisher's version, 519 KB, PDF-document

  • Appendices

    Final publisher's version, 783 KB, PDF-document

  • Complete thesis

    Final publisher's version, 1 MB, PDF-document

    Embargo ends: 02/06/2018

  • Propositions

    Final publisher's version, 130 KB, PDF-document

  • Jan Peter Yska
This thesis addresses several aspects of the optimal use of medication after bariatric surgery. The changes in the gastrointestinal tract after bariatric surgery may affect the efficacy and safety of medication. However, so far little is known on the effectiveness and safety of medication after bariatric surgery.

This thesis focuses on the following issues.

Metoprolol is widely used in the treatment of hypertension and cardiovascular diseases. A study in female patients showed that the bioavailability of metoprolol tablets may be affected by a specific type of bariatric procedure (Roux-en-Y gastric bypass). For patients using metoprolol after this type of surgery, close monitoring is necessary, with dosage adjustment of metoprolol if needed.

In spite of guidelines to avoid NSAIDs after surgery, their use by bariatric surgery patients is considerable. An intervention study to reduce the use of NSAIDs after bariatric surgery was not successful. Patients using NSAIDs after bariatric surgery may be at risk. Therefore further research is necessary.

With data from a very large UK primary health care database we showed that bariatric surgery strongly increases the chance of remission of type 2 diabetes mellitus. Bariatric surgery and, in particular, gastric bypass or sleeve gastrectomy, may be considered a realistic treatment option for type 2 diabetes mellitus.

Knowledge of bariatric surgical procedures and their possible influence on the use and bioavailability of medications, is an important condition of optimal medication surveillance.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Roon, van, Eric, Supervisor
  • Wilffert, Bob, Supervisor
  • Knibbe, Catherijne A. J., Assessment committee, External person
  • van Rossum, E. F. C., Assessment committee, External person
  • Touw, Daan, Assessment committee
Award date2-Jun-2017
Place of Publication[Groningen]
Print ISBNs978-90-367-9756-6
Electronic ISBNs978-90-367-9755-9
StatePublished - 2017

View graph of relations

Download statistics

No data available

ID: 41913556